

## **Kimberly M. Thompson, Sc.D.**

7512 Dr. Phillips Blvd. #50-523 Orlando, FL 32819  
617-680-2836, kimt@kidrisk.org

### **EDUCATION**

- 1995 Harvard University, School of Public Health, Doctor of Science in Environmental Health
- 1989 Massachusetts Institute of Technology, Master of Science in Chemical Engineering Practice
- 1988 Massachusetts Institute of Technology, Bachelor of Science in Chemical Engineering

### **ACADEMIC APPOINTMENTS**

- 2012-2018 University of Central Florida, College of Medicine, Professor of Preventive Medicine and Global Health
- 1997-2010 Harvard School of Public Health, Assistant Professor of Risk Analysis and Decision Science, Department of Health Policy and Management (1997-2002), Associate Professor of Risk Analysis and Decision Science, Departments of Health Policy and Management and Society, Human Development, and Health (previously Maternal and Child Health) (2002-2008), and Adjunct Associate Professor (October 2008-August 2010), member of the Harvard University Committee on Higher Degrees in Health Policy (2000-2007), member of the Harvard University-wide Committee on the Environment (1999-2007)
- 2003-9 Harvard Medical School, Children's Hospital Boston, Associate Professor of Risk Analysis and Decision Science (Department of Pediatrics), Associate Scientific Staff (Division of Adolescent Medicine)
- 2005-7 Massachusetts Institute of Technology, Sloan School of Management, Visiting Associate Professor in the System Dynamics Group
- 1989 Massachusetts Institute of Technology, Assistant Director of Chemical Engineering Practice School, Syntex Chemicals summer projects in Boulder, CO

### **OTHER POSITIONS**

- 2008- Kid Risk, Inc., Founder and President. Kid Risk, Inc. is a non-profit (501(c)(3)) organization established in October 2008 exclusively for the following research, charitable, and educational purposes: (a) to develop the field of pediatric risk analysis; (b) to empower children, parents, policy-makers and others to improve children's lives, (c) to inform decisions related to the management of children's risks, (d) to promote children's health and well-being ([www.kidrisk.org](http://www.kidrisk.org)).
- 2008- AORM, LLC, Founder and President. AORM, LLC helps risk managers find the best solutions in a variable, uncertain, and dynamic world. AORM provides consulting, education and training, communications, public speaking, and publishing services, and specializes in risk communication ([www.AORM.com](http://www.AORM.com)).
- 2000-9 Harvard University, Founding Director of the Harvard Kids Risk Project
- 2003-9 Children's Hospital Boston, Co-Founder of the Center on Media and Child Health

## **HONORS AND AWARDS**

- 2018 Distinguished Achievement Award, Society for Risk Analysis
- 2017 Best Paper Award, Society for Risk Analysis (with ND Badizadegan)
- 2014 Edelman Award, First Prize, U.S. Centers for Disease Control and Prevention (CDC)/Kid Risk, Inc. Team, INFORMS
- 2014 Edelman Laureate, INFORMS
- 2008 Jay Wright Forrester Award, System Dynamics Society
- 2008 Practice Award Finalist, Decision Analysis Society
- 2007 Fellow, Society for Risk Analysis
- 2007 World Champion, Beer Distribution Game, System Dynamics Society
- 2004 Chauncey Starr Distinguished Young Risk Analyst Award, Society for Risk Analysis
- 2003-5 Distinguished Lecturer, Sigma Xi/Society for Risk Analysis
- 2003 Outstanding Published Paper Demonstrating an Application of Risk Assessment, Society of Toxicology (with LM Sweeney, TR Tyler, CR Kirman, RA Corley, RH Reitz, DJ Paustenbach, JF Holson, MD Whorton, and ML Gargas)
- 2002 Bambi Holzer Health Literacy Award Honorable Mention, Institute for Healthcare Advancement
- 2001 Thomas T. Hoopes Prize faculty award, Harvard University, Faculty of Arts and Sciences (for work with Seamus Ryan on his Senior Thesis)
- 1990-1 Harvard University Scholarship
- 1989 Massachusetts Institute of Technology, David H. Koch Scholarship
- 1988 Massachusetts Institute of Technology, Department of Chemical Engineering, Practice School Fellowship

## **PROFESSIONAL MEMBERSHIPS**

### **INFORMS**

- Decision Analysis Society – Co-Chair of Student Paper Competition (2007)
- Society for Risk Analysis
  - Fellow (2007-present)
  - President (2006-2007)
  - President-Elect (2005-2006)
  - Councilor (2002-2005)
  - Historian (2003-2005)
  - Chair of the Exposure Assessment Specialty Group (1999)
- System Dynamics Society
  - Forrester Award Committee (2013-2018)

## **PROFESSIONAL SERVICE**

United States National Vaccine Advisory Committee (Term: 3/14/2015 - 9/14/2018, Chair: 6/8/2016 - 9/14/2018)

World Health Organization, Strategic Advisory Group of Experts (SAGE) Working Group on Polio (2008-2017)

#### National Academy of Sciences and Institute of Medicine

- Committee on the Health Implications of Raising the Minimum Age for Purchasing Tobacco Products (2014-2015)
- Board on Environmental Studies and Toxicology (2004-2010)
- Committee on Ranking FDA Product Categories, Phase I (2008)
- Committee on the Assessment of the Health Implications of Exposure to Dioxin (2004-2006)
- Invited briefing for the Committee on Biosensors (2002)
- Invited briefing for the Advisory Committee Meeting for the Office on Public Understanding of Science (2002)
- Committee for the Study of a Motor Vehicle Rollover Rating System (2002)
- Subcommittee to Update the 1999 Arsenic Report (2001)
- Subcommittee to Evaluate the Risks of the Atsugi Incinerator in Japan (2000)

Core Member of the Peer Consultation Panel for the Environmental Protection Agency Voluntary Children's Chemical Evaluation Program (VCCEP) (2002-2006)

Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention (2002-2005)

#### University Advisory Committee Positions

- University of Michigan School of Public Health, Dean's External Review Committee of Centers (2013)
- External Examiner, University of New South Wales, School of Information Technology and Electrical Engineering, Canberra, Australia (2008)
- Pardee RAND Graduate School, Advisory Council (2007-2008)
- External Examiner, Dublin Institute of Technology, MSc in Environmental Health Risk Management Course, School of Food Science and Environmental Health, Faculty of Tourism and Food (2002)

#### Harvard University Service

- Member of the Faculty Partners Committee, Office for Research Compliance, Harvard Medical School (2003-2005)
- Member of the Harvard Committee on Employee and Contracting Policy Implementation (2002-2003)
- Member of the Scientific Advisory Council for the Harvard Center for Public Health Preparedness (2002-2003)
- Member of the Harvard School of Public Health Faculty Council (2001-2004)
- Member of the Harvard University Risk Management Committee (2000-2004)

#### Board of Directors Positions

First Star (2003-2013)  
American Council on Science and Health (2002-2005)

#### Corporate Scientific Advisory Boards

Procter & Gamble, Sustainability Expert Advisory Panel (2009-2015)

Lake Nona Life Project, Johnson & Johnson and the Lake Nona Institute (2013-2014)  
Environ International Corporation/Grocery Manufacturers Association Advisory Panel (2012)

Procter & Gamble, Central Product Safety Division, External Advisory Board (2005-2012)  
The Dow Chemical Company, Toxicology and Environmental Research & Consulting Technical Advisory Board (2006-2008)

#### Editorial Boards

- Medical Decision Making (2008-2012)
- Risk Analysis (2008-present), Associate Editor for Engineering (2010-2012)
- Human and Ecological Risk Assessment, Software Review Editor and Senior Editor for Risk Communication (2002-2005)
- Journal of Children's Health, Associate Editor (2002-2005)

#### Peer reviewer for a diverse range of journals, including

American Journal of Epidemiology, American Journal of Public Health, Archives of Pediatrics and Adolescent Medicine, BMC Infectious Diseases, BMC Public Health, Bulletin of the World Health Organization, Environmental Health Perspectives, Environmental Science and Technology, Epidemics, Expert Review of Vaccines, Health Economics, Health Policy, Human and Ecological Risk Assessment, Journal of Adolescent Health, Journal of the Air and Waste Management Association, Journal of the American Medical Association, Journal of Exposure Analysis and Environmental Epidemiology, Journal of Health Economics, Journal of Health Services Research & Policy, Journal of Infectious Diseases, Journal of Pediatrics, Journal of Risk Research, Journal of Toxicology and Environmental Health, The Lancet, The Lancet Infectious Diseases, Management Science, Medical Decision Making, Medscape General Medicine/Medscape Journal of Medicine, New England Journal of Medicine, Pediatrics, PLoS Medicine, PLoS One, Reliability Engineering and System Safety, Risk Analysis, Science, System Dynamics Review, Vaccine, Value in Health

#### Grant reviewer for

- National Science Foundation
- U.S. Environmental Protection Agency
- U.S. Food and Drug Administration

#### **SELECTED INVITED PRESENTATIONS**

February 2022, "What Kind of World?" Keynote at the International Consumer Product Health and Safety Organization Annual Meeting, Washington, DC.

December 2021, "Contributions by Risk Analysts to COVID-19 Management." Plenary at the Society for Risk Analysis Annual Meeting, Virtual.

June 2018, "The Economic Case for Eradicating Polio." National Academy of Medicine Forum for Microbial Threats meeting on Understanding the Economics of Microbial Threats, Washington, DC.

December 2017, "Risk Analysis: An Obsolete Profession?" Plenary at the Society for Risk Analysis Annual Meeting, Arlington, VA.

July 2017, "Using integrated modeling to support the global eradication of vaccine-preventable diseases." Plenary for the 2017 International Conference of the System Dynamics Society, Cambridge, MA (with and presented by Duintjer Tebbens, RJ).

June 2016, "What is Risk Analysis and Why is it so Important?" Opening Keynote for course on Risk Analysis held by George Mason University Mercatus Center and Institute for Humane Systems, Portland, OR.

November 2014, "Polio Eradicators Use Integrated Analytical Models to Make Better Decisions." Keynote speaker at INFORMS, San Francisco, CA (with Duintjer Tebbens, RJ, Pallansch MA, Cochi, SL, video of Edelman Award Winning Presentation (available at: [https://www.pathlms.com/informs/events/217/thumbnail\\_video\\_presentations/5750](https://www.pathlms.com/informs/events/217/thumbnail_video_presentations/5750)).

August 2014, "Seeing the Big Picture: Systems Analysis and Disease Eradication." Keynote speaker at 1st Gordon Research Conference on Science & Technology Policy: Systems Approaches to Research and Practice, Waterville Valley, NH.

March 2013, "Understanding and Managing Complex Systems: Insights from Modeling Disease Eradication." Invited speaker at the 13th Annual Scientific Meeting of the American Academy of Health Behavior, Santa Fe, NM.

March 2013, "Fueling the Fire: Health, Research, and Life-long Learning." Keynote for the UCF College of Medicine 4th Annual FIRE Research Conference, Orlando, FL.

November 2011, "Integrated Policy Models in the Context of Managing Global Polio Risks." Plenary for the 2011 Association of Public Policy Analysis & Management Conference, Washington, DC.

October 2011, "Children at Risk." Session organizer and speaker for the 2011 Benefit-Cost Analysis Conference, Washington, DC.

July 2011, "Seeing Time: Using System Dynamics to Inform Public Health Choices." Plenary for the 2011 System Dynamics Society Conference, Washington, DC.

March 2011, "Using Models to Inform Policy: Insights from Modeling the Complexities of Global Polio Eradication," Keynote for the 4th International Conference on Social Computing, Behavioral-Cultural Modeling and Prediction, College Park, MD.

June 2010, "Using System Dynamics to Develop Policies that Matter: Polio Eradication and Beyond," Lecture in the Institute on Systems Science and Health, New York, NY.

March 2009, "Nutrition, Obesity, and Public Health," Keynote for Purdue Pugwash Conference, West Lafayette, IN.

December 2008, "Risk and Perspective," Keynote for Assessing, Managing and Communicating Environmental Risk: A Call to Action, Hubert H. Humphrey Institute of Public Affairs, Minneapolis, MN.

November 2008, "Leading with Analysis in the Age of Risk Management," Keynote at 2008 Palisade Risk and Decision Analysis Conference, New York, NY.

August 2008, "Prioritizing Food Risks," American College of Nutrition, Baltimore, MD.

July 2008, "Using System Dynamics to Develop Policies that Matter: Global Management of Poliomyelitis and Beyond," System Dynamics Society Conference, Jay Wright Forrester Award Lecture (with Radboud J. Duintjer Tebbens), Athens, Greece.

March 2008, "Polio Eradication and Risk Management: Insights from Global Health Policy Analyses," Duke University, Global Health Institute, Durham, NC.

December 2007, "Polio Eradication: Informing One of the World's Top Public Health Decisions," National Center for Immunization and Respiratory Diseases Monthly Seminar, Centers for Disease Control and Prevention, Atlanta, GA.

December 2007, "Prioritizing Food Risks," Improving Compliance with Dietary Recommendations: Time for New, Inventive Approaches?" USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX.

November 2007, "Perspectives on the Advancement of Risk Assessment," American College of Toxicology, Charlotte, NC.

November 2007, "Risk in Perspective: Effective Risk Communication," Seafood - Exploring Benefits and Risks, University of New Hampshire, Concord, NH.

September 2007, "Polio Eradication: What Can we Learn from Analysis?" Polio Immunization: Moving Forward, National Institutes of Health, Bethesda, MD.

July 2007, "Life in the Age of Risk Management: Putting Risk in Perspective," Keynote for the Industrial Water Quality 2007, Providence, RI.

March 2007, "Global Poliomyelitis Eradication: Challenges & Benefits," National Immunization Conference, Kansas City, MO.

February 2007, "Costs and Cases of Polio Eradication Compared to Control," WHO Urgent Stakeholder Consultation on Polio Eradication, World Health Organization, Geneva, Switzerland.

November 2006, "Strategy in the Age of Risk Management," Post Approval Drug Safety Strategies: Approaches and Processes to Reduce Risk, Cambridge Healthtech Institute, Philadelphia, PA.

November 2006, "The Age of Risk Management: Understanding the Basics of Risk and Benefit Analysis," Reporting on Consumer Health Risks and Benefits, Foundation for American Communications, Gannett Headquarters, McLean, VA, and Columbia School of Journalism, New York, NY.

October 2006, "Water, People, and the Blue Planet," Keynote Speaker for the American Academy of Microbiology Colloquium on Clean Water: What is Acceptable Microbial Risk? Tucson, AZ.

June 2006, "Testimony" given at Violent and Explicit Video Games: Informing Parents and Protecting Children Hearing by the Subcommittee on Commerce, Trade, and Consumer Protection, House Rayburn Building, Washington, DC (available at: <http://energycommerce.house.gov/108/Hearings/06142006hearing1921/hearing.htm>).

May 2006, "Navigating the Age of Risk Management," Keynote Speaker for the 2006 Project Risk Symposium, Houston, TX.

April 2006, "Media and Kids: What's in a Game?" Congressional Caucus on Sex and Violence in the Media, Washington, DC.

December 2005, 2006, and November 2007, "How to Think about Risks to Health and Safety," Medical Evidence Boot Camp, Knight Science Journalism Fellowship Program, Cambridge, MA.

October 2005, "Communicating Children's Health Risks," Communicating Children's Health Risks: A Symposium on Risk & the Media, National Consumers League, National Press Club, Washington, DC.

September 2005, "The Age of Risk Management," Keynote Speaker for the 2005 Risk Management and Finance Summit, Nonprofit Risk Management Center, San Francisco, CA.

September 2005, "Life in the Age of Risk Management," Philosophical Society of Washington, Meeting 2194, Washington, DC.

June 2005, "Retrospective Cost-Effectiveness Analyses for Polio Vaccination in the United States," National Immunization Program Seminar, Centers for Disease Control and Prevention, Atlanta, GA.

April 2005, "What's in a Game? Critical Information for Parents Raising Today's Media-Saturated Kids." (with Kevin Haninger), California PTA Meeting, Sacramento, CA.

April 2005, "Young People and Choices in the Age of Risk Management," Phillips Academy, Andover, MA.

March 2005, "Dangers to Children, Real and Perceived," The New Generation Gap: Barriers and Breakthroughs, Casey Journalism Center on Children and Families, College Park, MD.

November 2004, "Using Decision Analysis to Support Future PAHO Polio Vaccination Policies" (with Duintjer Tebbens RJ, Andrus JK, and Landaverde M), XVI Reunión del Grupo Técnico Asesor sobre Enfermedades Prevenibles por Vacunación, Organización Panamericana de la Salud (PAHO), Mexico City, Mexico.

September 2004, "Testimony" given at Effectiveness of Media Rating Systems Hearing by the U.S. Committee on Commerce, Science, and Transportation, Subcommittee on Science, Technology, and Space, Senate Russell Building, Washington, DC (available at: [http://commerce.senate.gov/hearings/testimony.cfm?id=1322&wit\\_id=3850](http://commerce.senate.gov/hearings/testimony.cfm?id=1322&wit_id=3850)).

September 2004, "Risk and Decision Analysis Research for Post-Certification," WHO Information Consultation on Research Towards Development of Post-Certification Polio Immunization Policy, World Health Organization, Geneva, Switzerland.

August 2004, "Decision Analysis of Post-Certification Polio Eradication Policies," National Immunization Program Seminar, Centers for Disease Control and Prevention, Atlanta, GA.

May 2004, "Risk Management and Integrated Decision Making," National Defense University, Washington, DC.

April 2004, "Understanding Children's Risks: The Need for Longitudinal Data," Studying Children's Health for a Better Tomorrow, U.S. House of Representatives, Cannon Office Building, Washington, DC.

April 2004, "Science in the Age of Risk Management," Keynote address at the Eastern Colleges Science Conference, Manhattan College, New York, NY.

November 2003, "Risk in Perspective," Compliance and Beyond: A Regulatory Seminar, MTL-ACTS, New York, NY.

September 2003, "Decision Analytic Research on Post-Certification Immunization Policies: An Update," WHO Informal Consultation on Research towards Development of Post-Certification Polio Immunization Policy, World Health Organization, Geneva, Switzerland.

July 2003, "The Role of Risk Analysis in Product Design and Regulation," Toy Industry Association, Multi-Discipline Conference for Safety, Trade, Logistics and Credit Professionals, Chicago, IL.

February 2003, "Life in the Age of Risk Management," Keynote Address at the International Consumer Product Health and Safety Organization Meeting, Orlando, FL.

February 2003, "The Media: Peril and Promise," (with Michael Rich), National Chamber of Commerce and the National Chamber Foundation Annual Board meetings, Boca Raton, FL.

February 2003, "Making Peace with Germs," 92nd St. Y, New York, NY.

December 2002, "Addressing Uncertainty and the Use of Precaution in Risk Analysis," Risk Assessment Science Forum, Ottawa, Canada.

October 2002, "Decision Analytic Research on Post-Certification Immunization Policies," WHO Informal Consultation on Economics Research on Post-Certification Immunization Policies, World Health Organization, Geneva, Switzerland.

September 2002, "Sensors: What Can They Tell Me?" National Defense University, Washington, DC.

July 2002, “Dealing with Microbiological Risks in the Age of Risk Management: Putting the Public Back into Public Health,” 1st International Conference on Microbiological Risk Assessment: Foodborne Hazards, Baltimore, MD.

April 2002, “Improving Public Health Measures: Advances in Risk Analysis,” New England Bioterrorism Preparedness Workshop, MIT Lincoln Laboratory, Lexington, MA.

November 2001, “What's in Popular Children's Entertainment Media and Why You Should Care,” Advances in Pediatric Health Care, Children's Hospital, Boston, MA.

May 2001, “Understanding and Communicating Risk,” Population Council, New York, NY.

May 2001, “Risk Communication,” Seminar on Risk and Human and Organizational Factors, Ship Structure Committee (US Intergovernmental Advisory Committee), Washington, DC.

March 2001, “Media Messages and Youth Health,” (with Michael Rich), City of Boston Symposium on Youth Development, Boston, MA.

February 2001, “Children's Risks in the New Millennium” and “Children's Risks and Nutrition,” Nutrition Information Service of the USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX.

January 2001, “Comments on CVM Approach: Risk Assessor Perspective,” Use of Antimicrobial Drugs in Food Animals and the Establishment of Regulatory Thresholds on Antimicrobial Resistance Public Meeting sponsored by US FDA, Rockville, MD.

May 2000, “Navigating the Maze: Federal Activities to Address Children's Environmental Health Risks,” Children's Environmental Risks: Federal Activities in Perspective, sponsored by the Congressional Research Service, Washington, DC.

March 2000, “Relative Risk: What Consumer Products are Most Dangerous?” Consumer Assembly 2000, Annual Meeting of the Consumer Federation of America, Washington, DC.

January 2000, “Children's Risks: Evaluating Hazard Claims and Setting Priorities,” National Consumers League forum on Analyzing the Threats to Children from Consumer Products: A Symposium on Risk Assessment and Risk Communication, National Press Club, Washington, DC.

September 1999, “Guiding Principles for Preparing Aggregate Exposure Assessments,” National Institutes of Health/National Institute of Environmental Health Sciences Workshop on the Role of Human Exposure Assessment in the Prevention of Environmental Disease, Rockville, MD.

November 1998, “Environmental Risk Management and Risk Ranking in the USA: Lessons and Experiences,” Seminario Manejo Y Comunicacion De Riesgos Ambientales: Nuevos Desafios Para Chile, sponsored by the University of Chile and CONAMA, Santiago, Chile.

March 1998, “Developing Distributions from Data,” Practical Issues in the Use of Probabilistic Risk Assessment and its Applications to Hazardous Waste Sites Conference, sponsored by the EPA Superfund Basic Research Program and the National Institute for Environmental Health Sciences, Sarasota, FL.

## **RESEARCH FUNDING (as Principal Investigator)**

Bill & Melinda Gates Foundation

- “Characterizing Uncertainty in Long-term Poliovirus Risks to Support Further Research and Risk Management Decisions” (Grant INV-009333 / OPP1129391-2015, May 2015-April 2023).
- “Using Models to Support Planning and Management Activities for the Polio Endgame” (Contract 4533-25298, February 2014-February 2015).



- “Benefits of Investing in the Polio Endgame” (Contract 4533-23446, March 2013-January 2014).
- “Accelerating Eradication: Development of an Optimization Tool to Cost-Effectively Achieve Optimal Population Immunity and Track Progress” (Contract 4533-21031, January 2012-December 2012).
- “Identification of Decision Options and Strategies for Achieving the Eradication of Wild Polioviruses Phase II” (Contract 4533-18487, January 2011-December 2011).
- “Identification of Decision Options and Strategies for Achieving the Eradication of Wild Polioviruses Phase I” (Contract 4533-17492, January 2010-August 2010).

#### U.S. Centers for Disease Control and Prevention

- “Integrated Modeling to Support the Global Polio Eradication Initiative (GPEI) and Management of Other Vaccine Preventable Diseases” (Cooperative Agreement NU2RGH001915, April 2021-April 2026).
- “Integrated Economic, Dynamic Disease, Risk and Decision Analytic Modeling of Global and Domestic Policy Issues for Polio” (Cooperative Agreement U2RGH001913, April 2016-April 2021).
- “Support of Decision Making for Global Switch from tOPV to bOPV Using Integrated Modeling” (Contract 200-2015-M-63078, July 2015-June 2016).
- “Characterization of Outbreak Response Strategies and Forecasting of Vaccine Stockpile Needs for the Polio Endgame” (Contract 200-2015-M-61344, November 2014-October 2015).
- “Integrated Economic, Dynamic Disease, Risk and Decision Analytic Modeling” (Cooperative Agreement U66IP000519, September 2011-August 2014).
- “Quantification of the Role of Secondary OPV Exposure for Different Serotypes in Providing Population Immunity” (Contract 200-2010-M-35172, July 2010-January 2011).
- “Trends in the Risk of U.S. Polio Outbreaks and Poliovirus Vaccine Availability for Response” (Contract 200-2010-M-33679, March 2010-June 2010).
- “Review of Polio Immunity States as a Function of Exposure to Live and Inactivated Polioviruses and Implications for Improving Dynamic Modeling of Poliovirus Transmission” (Contract 200-2010-M-33379, January 2010-July 2010).
- “Assessment of the Value of Global Polio Vaccination and Willingness-to-Pay” (Cooperative Agreement 5U66IP000169, November 2007-October 2010).
- “Joint Initiative in Vaccine Economics (JIVE) Projects I and II” (Co-PI on Cooperative Agreements U50CCU300860 and 3U01IP000029, PI on global health component, September 2001-September 2008)

#### World Health Organization

- “Modeling the benefits of 50 years of polio vaccine in the Expanded Program on Immunization” (PI, WHO Registration 2023/1423795-0 and 2023/1423800-0, December 2023-February 2024).
- “Modeling the Costs and Benefits of Temporary Recommendations for Poliovirus Exporting Countries to Vaccinate International Travelers” (Co-PI, WHO Registration 2016/670796-0 with the Global Polio Eradication Initiative, October 2016-January 2017).

- “The Development of Measles Eradication and Mortality Reduction Investment Cases With and Without Rubella” (WHO Registration 2011/181545-0 and 2012/217414-0 with the Expanded Programme on Immunization, October 2011-October 2013).
- “Development of an Extended Dynamic Model for Poliovirus Transmission for Analysis of OPV Cessation Timing and Post-Eradication Outbreak Response Issues” (WHO Registration 2009/23464-0 and 2010/62760-0 with the Polio Research Committee, April 2009-December 2011).

#### Annie E. Casey Foundation

- “Corporate Commitment to Children” (2004).
- “Do Kids Count in the Board Room?” (2002).

#### Others

- Kid Risk, Unrestricted gifts from private individuals and corporations (2011-2024).
- Kids Risk Project, Harvard University, Unrestricted gifts from private individuals and corporations (2000-2010).
- MIT Lincoln Laboratory, “Urban Biodefense Initiative” (2003-2004).
- Chlorine Chemistry Council, “Development of a Guide to Aid in the Evaluation of Communications of Health-Related Scientific Information” (1998-1999).
- Public Health Advisory Board, “Analysis of cost-effectiveness strategies for children and of federal resource allocations for children's health” (1998).

## BIBLIOGRAPHY

### *Refereed Journal Articles*

1. **Thompson KM**, Burmaster DE. Parametric distributions for soil ingestion by children. *Risk Analysis* 1991; 11(2):339-342.
2. **Thompson KM**, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. *Risk Analysis* 1992; 12(1):53-63.
3. Koutrakis P, **Thompson KM**, Wolfson JM, Spengler JD, Keeler GJ, Slater J. Determination of aerosol strong acidity losses due to interactions of collected particles: Results from laboratory and field studies. *Atmospheric Environment* 1992; 26A(6):987-995.
4. **Thompson KM**, Evans JS. Workers' breath as a source of perchloroethylene (Perc) in the home. *Journal of Exposure Analysis and Environmental Epidemiology* 1993; 3(4):417-430.
5. Burmaster DE, Lloyd KJ, **Thompson KM**. The need for new methods to backcalculate soil cleanup targets in interval and probabilistic cancer risk assessments. *Human and Ecological Risk Assessment* 1995; 1(1):89-100.
6. Burmaster DE, **Thompson KM**. Backcalculating cleanup targets in probabilistic risk assessments when the acceptability of cancer risk is defined under different risk management policies. *Human and Ecological Risk Assessment* 1995; 1(1):101-120.
7. **Thompson KM**, Graham JD. Going beyond the single number: Using probabilistic risk assessment to improve risk management. *Human and Ecological Risk Assessment* 1996; 2(4):1008-1034.
8. **Thompson KM**, Evans JS. The value of improved national exposure information for perchloroethylene (Perc): A case study for dry cleaners. *Risk Analysis* 1997; 17(2):253-271.

9. Burmaster DE, **Thompson KM**. Estimating exposure point concentrations for surface soils for use in deterministic and probabilistic risk assessments. *Human and Ecological Risk Assessment* 1997; 3(3):363-384.
10. Graham JD, **Thompson KM**, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of airbags by seating position. *Journal of the American Medical Association* 1997; 278:1418-1425, Letter 279:506-507.
11. Graham JD, Goldie SJ, Segui-Gomez M, **Thompson KM**, Nelson T, Glass R, Simpson A, Woerner LG. Reducing risks to children in vehicles with passenger air bags. *Pediatrics* 1998; 102(1):e3 (available at <http://www.pediatrics.org/cgi/content/full/102/1/e3>).
12. Burmaster DE, **Thompson KM**. Fitting second-order parametric distributions to data using maximum likelihood estimation. *Human and Ecological Risk Assessment* 1998; 4(2):319-339.
13. Koop CE, Juberg DR, Benedek EP, Brecher RW, Brent RL, Cole P, Corn M, Covello V V, Downes TW, Gad SC, Gold LS, Guengerich FP, Higginson J, Konemann WH, Lamb IV JC, Liroy PJ, Lundberg GD, **Thompson KM**. A scientific evaluation of health effects of two plasticizers used in medical devices and toys: A report from the American Council on Science and Health. *Medscape General Medicine* 1999(June 22); 1(1) (available at: <http://www.medscape.com/viewarticle/407990>), Letter at: *Medscape General Medicine* 2000(May 26); 2(2) (available at: <http://www.medscape.com/viewarticle/408056>).
14. **Thompson KM**, Segui-Gomez M, Graham JD. Validating analytical judgments: The case of the airbag's lifesaving effectiveness. *Reliability Engineering and System Safety* 1999; 66(1):57-68.
15. Segui-Gomez M, Levy J, Roman H, **Thompson KM**, McCabe K, Graham JD. Driver distance from the steering wheel: Perception and objective measurement. *American Journal of Public Health* 1999; 89(7):1109-1111.
16. **Thompson KM**. Developing univariate distributions from data for risk analysis. *Human and Ecological Risk Assessment* 1999; 5(4):755-783.
17. Burmaster DE, **Thompson KM**. Using animated probability plots to explore the suitability of mixture models with two component distributions. *Risk Analysis* 1999; 19(6):1185-1192.
18. Lofstedt RE, Ikeda S, **Thompson KM**. Risk management across the globe: Insights from a comparative look at Sweden, Japan, and the United States. *Risk Analysis* 2000; 20(2):157-161.
19. Yokota F, **Thompson KM**. Violence in G-rated animated feature films. *Journal of the American Medical Association* 2000; 283:2716-2720.
20. **Thompson KM**, Bloom DL. Communication of risk assessment information to risk managers. *Journal of Risk Research* 2000; 3(4):333-352.
21. Evans JS, **Thompson KM**, Hattis D. Exposure efficiency: Concept and application to perchloroethylene exposure from dry cleaners. *Journal of the Air & Waste Management Association* 2000; 50:1700-1703.
22. Juberg DR, Alfano K, Coughlin RJ, **Thompson KM**. An observational study of object mouthing behavior by young children. *Pediatrics* 2001; 107(1):135-142.
23. Burmaster DE, **Thompson KM**. Fitting a second-order parametric distribution conditioned on an explanatory variable using maximum likelihood estimation. *Journal of Risk Research* 2001; 4(1):49-62.
24. **Thompson KM**, Yokota F. Depiction of alcohol, tobacco, and other substances in G-rated animated feature films. *Pediatrics* 2001; 107(6):1369-74.
25. Sweeney LM, Tyler TR, Kirman CR, Corley RA, Reitz RH, Paustenbach DJ, Holson JF, Whorton MD, **Thompson KM**, Gargas ML. Proposed occupational exposure limits for select

- ethylene glycol ethers using PBPK models and Monte Carlo simulations. *Toxicological Sciences* 2001; 62(1):124-139.
26. **Thompson KM**, Haninger K. Violence in E-rated video games. *Journal of the American Medical Association* 2001; 286(5):591-598, Letter 286(16):1972.
  27. Claxton K, **Thompson KM**. A dynamic programming approach to the efficient design of clinical trials. *Journal of Health Economics* 2001; 20:797-822.
  28. Ko G, Burge HA, Nardell EA, **Thompson KM**. Estimation of tuberculosis risk and incidence under upper room ultraviolet germicidal irradiation in a waiting room in a hypothetical scenario. *Risk Analysis* 2001; 21(4):657-673.
  29. **Thompson KM**, Rabouw RF, Cooke RM. The risk of groundling fatalities from unintentional airplane crashes. *Risk Analysis* 2001; 21(6):1025-1037.
  30. Cohen JT, Carlson G, Charnley G, Coggon D, Delzell E, Graham JD, Greim H, Krewski D, Medinsky M, Monson R, Paustenbach D, Petersen B, Rappaport S, Rhomberg L, Ryan PB, **Thompson KM**. A comprehensive evaluation of the potential health risks associated with occupational and environmental exposure to styrene. *Journal of Toxicology and Environmental Health* 2002; 5(1-2):1-263.
  31. **Thompson KM**. Variability and uncertainty meet risk management and risk communication. *Risk Analysis* 2002; 22(3):647-654.
  32. **Thompson KM**, Segui-Gomez M, Graham JD. Validating benefit and cost estimates: The case of airbag regulation. *Risk Analysis* 2002; 22(4):803-811.
  33. Lieu TA, **Thompson KM**, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics -- Perspectives from the United States. *Expert Review of Vaccines* 2002; 1(4):89-98.
  34. Marcy TW, Stefanek M, **Thompson KM**. Genetic testing for lung cancer risk: If we can do it, should we? *Journal of General Internal Medicine* 2002; 17(12):946-51.
  35. **Thompson KM**. The role of bath seats in unintentional infant bathtub drowning deaths. *Medscape General Medicine* 2003(March 26); 5(1) (available at: <http://www.medscape.com/viewarticle/450989>).
  36. **Thompson KM**. How much do kids count in corporate board rooms? Results from the first survey of Fortune 1000 companies. *Medscape General Medicine* 2003(March 26); 5(1) (available at: <http://www.medscape.com/viewarticle/451188>).
  37. Ryan MS, **Thompson KM**. When domestic environmental policy meets international trade policy: Venezuela's challenge to the U.S. gasoline rule. *Human and Ecological Risk Assessment* 2003; 9(3):811-827.
  38. Sangruejee NK, Duintjer Tebbens RJ, Cáceres VM, **Thompson KM**. Policy decision options during the first five years following certification of polio eradication. *Medscape General Medicine* 2003(December 19); 5(4):35 (available at: <http://www.medscape.com/viewarticle/464841>).
  39. Haninger K, **Thompson KM**. Content and ratings of teen-rated video games. *Journal of the American Medical Association* 2004; 291(7):856-865.
  40. Haninger K, Ryan MS, **Thompson KM**. Violence in teen-rated video games. *Medscape General Medicine* 2004(March 11); 6(1) (available at: <http://www.medscape.com/viewarticle/468087>).
  41. Ko G, **Thompson KM**, Nardell EA. Estimation of tuberculosis risk on a commercial airliner. *Risk Analysis* 2004; 24(2):379-387.
  42. Yokota F, **Thompson KM**. Value of information literature analysis (VOILA): A review of applications in health risk management. *Medical Decision Making* 2004; 24(3):287-298.

43. Vinturella AE, Burgess RM, Coull BA, **Thompson KM**, Shine JP. The use of passive samplers to mimic uptake of PAHs by benthic polychaetes. *Environmental Science and Technology* 2004; 38(4):1154-1160.
44. Yokota F, **Thompson KM**. Value of information (VOI) analysis in environmental health risk management (EHRM). *Risk Analysis* 2004; 24(3):635-650.
45. **Thompson KM**, Yokota F. Violence, sex, and profanity in films: Correlation of movie ratings and content. *Medscape General Medicine* 2004(July 13); 6(3). (available at: <http://www.medscape.com/viewarticle/480900>).
46. **Thompson KM**. Changes in children's exposure as a function of age and the relevance of age definitions for exposure and risk assessment. *Medscape General Medicine* 2004(July 20); 6(3) (available at: <http://www.medscape.com/viewarticle/480733>).
47. Vinturella AE, Burgess RM, Coull BA, **Thompson KM**, Shine JP. The importance of black carbon in equilibrium partitioning models of PAHs in contaminated marine sediments. *Environmental Toxicology & Chemistry* 2004; 23(11):2578-2586.
48. Williams RA, **Thompson KM**. Integrated analysis: Combining risk and economic assessments while preserving the separation of powers. *Risk Analysis* 2004; 24(6):1613-1623.
49. Yokota F, Gray G, Hammitt JK, **Thompson KM**. Tiered chemical testing: A value of information approach. *Risk Analysis* 2004; 24(6):1625-1639.
50. **Thompson KM**. Addicted media: Substances on screen. *Child and Adolescent Psychiatric Clinics of North America* 2005; 14:473-489.
51. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, **Thompson KM**. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. *American Journal of Epidemiology* 2005; 162(4):358-372.
52. Wendler D, Belsky L, **Thompson KM**, Ezekiel JE. Quantifying the federal minimal risk standard: Implications for 'non-beneficial' pediatric research. *Journal of the American Medical Association* 2005; 294(7):826-832.
53. **Thompson KM**, Deisler PD, Schwing D. Interdisciplinary vision: The first 25 years of the Society for Risk Analysis (SRA), 1980-2005. *Risk Analysis* 2005; 25(6):1333-1386.
54. Riederer AM, **Thompson KM**, Fuentes JM, Ford TE. Body weight and water ingestion estimates for women in two communities in the Philippines: The importance of collecting site-specific data. *International Journal of Hygiene and Environmental Health* 2006; 209(1):69-80.
55. Lee LK, Mao C, **Thompson KM**. Demographic factors and their association with outcomes in pediatric submersion injury. *Academic Emergency Medicine* 2006; 13(3):308-313.
56. **Thompson KM**, Tepichin K, Haninger K. Content and ratings of mature-rated video games. *Archives of Pediatrics and Adolescent Medicine* 2006; 160:402-410.
57. Wilson KM, Rimm EB, **Thompson KM**, Mucci LA. Dietary acrylamide and cancer risk in humans: A review. *Journal of Consumer Protection and Food Safety (J. Verbr. Lebensm)* 2006; 1:19-27.
58. Talmor D, **Thompson KM**, Legedza ATR, Nirula R. Predicting severe head injury after light motor vehicle crashes: Implications for automatic crash notification systems. *Accident Analysis and Prevention* 2006; 38(4):767-771.
59. **Thompson KM**. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. *Risk Analysis* 2006; 26(6):1419-1421.
60. **Thompson KM**, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Analysis* 2006; 26(6):1423-1440.
61. Aylward RB, Sutter RW, Cochi SL, **Thompson KM**, Jafari H, Heymann D. Risk management in a polio-free world. *Risk Analysis* 2006; 26(6):1441-1448.

62. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, **Thompson KM**. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. *Risk Analysis* 2006; 26(6):1471-1505.
63. Duintjer Tebbens RJ, Sangrujee N, **Thompson KM**. The costs of future polio risk management policies. *Risk Analysis* 2006; 26(6):1507-1531.
64. **Thompson KM**, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. *Risk Analysis* 2006; 26(6):1541-1556.
65. de Gourville E, Duintjer Tebbens RJ, Sangrujee N, Pallansch MA, **Thompson KM**. Global surveillance and the value of information: The case of the global polio laboratory network. *Risk Analysis* 2006; 26(6):1557-1569.
66. **Thompson KM**, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL. Perspective: Development and consideration of global policies for managing the future risks of poliovirus outbreaks: Insights and lessons learned through modeling. *Risk Analysis* 2006; 26(6):1571-1580.
67. Lee LK, **Thompson KM**. Parental survey of beliefs and practices about bathing and water safety and their children: Guidance for drowning prevention. *Accident Analysis and Prevention* 2007; 39(1):58-62.
68. Nigrovic LE, **Thompson KM**. The Lyme vaccine: A cautionary tale. *Epidemiology and Infection* 2007; 135(1):1-8.
69. **Thompson KM**, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. *The Lancet* 2007; 369(9570):1363-71.
70. Duintjer Tebbens RJ, **Thompson KM**, Huninck MGM, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. *Medical Decision Making* 2008; 28(2):182-200.
71. **Thompson KM**, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of future global policies for managing polioviruses. *American Journal of Public Health* 2008; 98(7):1322-1330.
72. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, **Thompson KM**. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. *Risk Analysis* 2008; 28(4):855-876.
73. **Thompson KM**, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. *Medscape Journal of Medicine* 2008; 10(8):190 (available at: <http://www.medscape.com/viewarticle/578396>).
74. Bier DM, Derelian D, German JB, Katz DL, Pate RR, **Thompson KM**. Improving compliance with dietary recommendations: Time for new, inventive approaches? *Nutrition Today* 2008; 43(5):180-187.
75. **Thompson KM**, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. *System Dynamics Review* 2008; 24(4):433-449.
76. Duintjer Tebbens RJ, **Thompson KM**. Priority shifting and the dynamics of managing eradicable infectious diseases. *Management Science* 2009; 55(4):650-663.
77. Duintjer Tebbens RJ, Pallansch MA, Alexander J, **Thompson KM**. Optimal vaccine stockpile design for an eradicated disease: Application to polio. *Vaccine* 2010; 28(26):4312-4327.

78. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, **Thompson KM**. Economic analysis of the Global Polio Eradication Initiative. *Vaccine* 2011; 29(2):334-343.
79. Rahmandad H, Hu K, Duintjer Tebbens RJ, **Thompson KM**. Development of an individual-based model for polioviruses: Implications of the selection of network type and outcome metrics. *Epidemiology and Infection* 2011; 139:836-848.
80. Badizadegan K, **Thompson KM**. Value of information in non-focal colonic biopsies. *Journal of Pediatric Gastroenterology and Nutrition* 2011; 53(6):679-683.
81. **Thompson KM**, Wallace GS, Duintjer Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SGF. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. *Public Health Reports* 2012; 127(1):23-37.
82. **Thompson KM**, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. *Expert Review of Vaccines* 2012; 11(4):449-459.
83. Kalkowska DA, Duintjer Tebbens RJ, **Thompson KM**. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. *American Journal of Epidemiology* 2012; 175(9):936-949.
84. Goodson JL and other WHO Measles and Rubella Research Meeting Work Group Leads (Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, **Thompson KM**, Martin R, Reef S, Strebel PM). Research priorities for global measles and rubella control and eradication. *Vaccine* 2012; 30(32):4709-16.
85. **Thompson KM**. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. *ICU Management* 2012; 12(4):9-11.
86. **Thompson KM**, Duintjer Tebbens RJ. Development of investment cases for globally-coordinated management of infectious diseases. *Journal of Vaccines and Vaccination* 2012; 3:164, doi:10.4172/2157-7560.1000164.
87. **Thompson KM**, Dabbagh A, Strebel PM, Perry R, Gacic-Dobo M, Cochi SL, Cairns L, Reef S. National and global options for managing the risks of measles and rubella. *Journal of Vaccines and Vaccination* 2012; 3:165, doi:10.4172/2157-7560.1000165.
88. Hennelly KE, Mannix R, Nigrovic L, Lee LK, **Thompson KM**, Monuteaux MC, Proctor M, Schutzman S. Pediatric traumatic brain injury and radiation risks: A clinical decision analysis. *Journal of Pediatrics* 2013; 162(2):392-397.
89. **Thompson KM**, Strebel PM, Dabbagh A, Cherian T, Cochi SL. Enabling implementation of the Global Vaccine Action Plan: Developing investment cases for globally managing measles and rubella. *Vaccine* 2013; 31S:B149-B156.
90. **Thompson KM**. Modeling poliovirus risks and the legacy of polio eradication. *Risk Analysis* 2013; 33(4):505-515.
91. **Thompson KM**, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Kim JH, Cochi SL. Pre-eradication national vaccine policy options for poliovirus infection and disease control. *Risk Analysis* 2013; 33(4):516-543.
92. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim JH, **Thompson KM**. Expert review on poliovirus immunity and transmission. *Risk Analysis* 2013; 33(4):544-605.
93. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim JH,

- Thompson KM.** Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. *Risk Analysis* 2013; 33(4):606-646.
94. **Thompson KM,** Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. *Risk Analysis* 2013; 33(4):647-663.
  95. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste S, Diop O, Wassilak SGF, Cochi SL, **Thompson KM.** Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses. *Risk Analysis* 2013; 33(4):680-702.
  96. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, **Thompson KM.** Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. *Risk Analysis* 2013; 33(4):703-749.
  97. **Thompson KM,** Duintjer Tebbens RJ, Chaignat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC. Managing cholera as a preventable global threat. *Journal of Vaccines and Vaccination* 2013; 4:183, doi:10.4172/2157-7560.1000183.
  98. **Thompson KM,** Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. *Expert Review of Vaccines* 2014; 13(2):221-234.
  99. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, **Thompson KM.** The potential impact of expanding target age groups for polio immunization campaigns. *BMC Infectious Diseases* 2014; 14:45, doi:10.1186/s12879-015-0791-5.
  100. Kalkowska DA, Duintjer Tebbens RJ, **Thompson KM.** Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. *Journal of Infectious Diseases* 2014; 210(S1):398-411.
  101. Kalkowska DA, Duintjer Tebbens RJ, **Thompson KM.** Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *Journal of Infectious Diseases* 2014; 210(S1):412-423.
  102. Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SGF, **Thompson KM.** Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. *Journal of Infectious Diseases* 2014; 210(S1):424-433.
  103. **Thompson KM,** Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. *Journal of Infectious Diseases* 2014; 210(S1):475-484.
  104. Duintjer Tebbens RJ, **Thompson KM.** Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. *Journal of Infectious Diseases* 2014; 210(S1):485-497.
  105. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman L, Anis E, Wassilak SGF, Pallansch MA, Cochi SL, **Thompson KM.** Modeling options to manage population immunity and the impact of asymptomatic wild poliovirus transmission in Israel. *Journal of Infectious Diseases* 2015; 211(11):1800-1812.
  106. **Thompson KM,** Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL. Polio eradicators use integrated analytical models to make better decisions. *Interfaces* 2015; 45(1):5-25.
  107. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, **Thompson KM.** Modeling undetected live poliovirus circulation after apparent interruption of transmission: Implications for surveillance and vaccination. *BMC Infectious Diseases* 2015; 15:66, doi:10.1186/s12879-015-0791-5.



108. **Thompson KM**, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of live polioviruses. *Vaccine* 2015; 33:1568-1577.
109. Berera D, **Thompson KM**. Medical student knowledge, attitudes, and practices regarding immunization. *Journal of Vaccines and Vaccination* 2015; 6:1, doi:10.4172/2157-7560.1000268.
110. Duintjer Tebbens RJ, Pallansch MA, Wassalik SGF, Cochi SL, **Thompson KM**. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *PLoS One* 2015; 10(6):e0130123, doi:10.1371/journal.pone.0130123.
111. Duintjer Tebbens RJ, Pallansch MA, **Thompson KM**. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. *BMC Infectious Diseases* 2015; 15:379, doi:10.1186/s12879-015-1115-5.
112. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassalik SGF, **Thompson KM**. An economic analysis of poliovirus risk management policy options for 2013-2052. *BMC Infectious Diseases* 2015; 15:389, doi:10.1186/s12879-015-1112-8.
113. **Thompson KM**, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. *BMC Infectious Diseases* 2015; 15:376, doi:10.1186/s12879-015-1116-4.
114. Duintjer Tebbens RJ, **Thompson KM**. Managing the risk of circulating vaccine-derived poliovirus during the endgame: Oral poliovirus vaccine needs. *BMC Infectious Diseases* 2015; 15:390, doi:10.1186/s12879-015-1114-6.
115. **Thompson KM**, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. *BMC Infectious Diseases* 2015; 15:374, doi:10.1186/s12879-015-1113-7.
116. **Thompson KM**, Badizadegan ND. Valuing information in supply chains: Optimal performance in the beer distribution game. *IEEE Access* 2015; 15(3):2677-2686, doi:10.1109/ACCESS.2015.2505730.
117. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassalik SGF, **Thompson KM**. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. *BMC Infectious Diseases* 2016; 16:137, doi:10.1186/s12879-016-1465-7.
118. Duintjer Tebbens RJ, Hampton LM, **Thompson KM**. Implementation of coordinated serotype 2 oral poliovirus vaccine cessation: Risks of potential non-synchronous cessation. *BMC Infectious Diseases* 2016; 16:231, doi:10.1186/s12879-016-1536-9.
119. Duintjer Tebbens RJ, Hampton LM, **Thompson KM**. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: Risks of inadvertent trivalent oral poliovirus vaccine use. *BMC Infectious Diseases* 2016; 16:237, doi:10.1186/s12879-016-1537-8.
120. **Thompson KM**, Cochi SL. Modeling and managing the risks of measles and rubella: A global perspective, Part I. *Risk Analysis* 2016; 36(7):1288-1296.
121. **Thompson KM**, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. *Risk Analysis* 2016; 36(7):1297-1314 (online 2014; Dec 24. doi:10.1111/risa.12331).
122. **Thompson KM**, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. *Risk Analysis* 2016; 36(7):1315-1331 (online 2014; Aug 5. doi:10.1111/risa.12264).

123. Simons EA, Reef SE, Cooper LZ, Zimmerman L, **Thompson KM**. Systematic review of the manifestations of Congenital Rubella Syndrome in infants and characterization of disability-adjusted life years (DALYs). *Risk Analysis* 2016; 36(7):1332-1356 (online 2014; Aug 12. doi:10.1111/risa.12263).
124. **Thompson KM**, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. *Risk Analysis* 2016; 36(7):1357-1382 (online 2015; Aug 5. doi:10.1111/risa.12459).
125. **Thompson KM**. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. *Risk Analysis* 2016; 36(7):1383-1403 (online 2016; Jun 9. doi:10.1111/risa.12637).
126. **Thompson KM**, Kisjes KH. Modeling measles transmission in the North America Amish and options for outbreak response. *Risk Analysis* 2016; 36(7):1404-1417 (online 2015; Jun 22. doi:10.1111/risa.12440).
127. **Thompson KM**, Logan GE, Research Team from Florida SHOTS™. Characterization of heterogeneity in childhood immunization coverage in Central Florida using immunization registry data. *Risk Analysis* 2016; 36(7):1418-1426 (online 2015; Jun 2. doi:10.1111/risa.12414).
128. **Thompson KM**, Odahowski CL, Goodson JL, Reef SE, Perry RT. Synthesis of evidence to characterize national historical measles and rubella immunization and exposure histories. *Risk Analysis* 2016; 36(7):1427-1458 (online 2015; Aug 6. doi:10.1111/risa.12454).
129. **Thompson KM**, Odahowski CL. Systematic review of measles and rubella serology studies. *Risk Analysis* 2016; 36(7):1459-1486 (online 2015; Jun 16. doi:10.1111/risa.12430).
130. **Thompson KM**, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: Application to measles and cholera vaccines as contrasting examples. *Risk Analysis* 2016; 36(7):1487-1509 (online 2014; Aug 11. doi:10.1111/risa.12265).
131. Rota PA, Moss WJ, Takeda M, de Swart RL, **Thompson KM**, Goodson JL. Measles. *Nature Reviews Disease Primers* 2016; 2:16049 (online 2016; Jul 14, doi:10.1038/nrdp.2016.49).
132. Duintjer Tebbens RJ, **Thompson KM**. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management. *Journal of Vaccines and Vaccination* 2016; 7:5; doi:10.4172/2157-7560.1000339.
133. Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, **Thompson KM**. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. *Journal of Vaccines and Vaccination* 2016; 7:5, doi:10.4172/2157-7560.1000340.
134. Duintjer Tebbens RJ, **Thompson KM**. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. *Future Microbiology* 2016; 11(12):1549-61.
135. Duintjer Tebbens RJ, **Thompson KM**. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: An essential OPV cessation risk management strategy. *Epidemiology and Infection* 2017; 145(2):217-226, doi:10.1017/S0950268816002302.
136. Duintjer Tebbens RJ, **Thompson KM**. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. *Medical Decision Making Policy and Practice* 2017; 2(1):1-13, doi:10.1177/2381468317697002.

137. Duintjer Tebbens RJ, **Thompson KM**. Poliovirus vaccination during the endgame: Insights from integrated modeling. *Expert Review of Vaccines* 2017; 16(6):577-586.
138. Duintjer Tebbens RJ, **Thompson KM**. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. *Vaccine* 2017; 35(31):3823-3833.
139. **Thompson KM**, Duintjer Tebbens RJ. Lessons from globally-coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. *Journal of Infectious Diseases* 2017; 216(S1):168-175.
140. **Thompson KM**, Duintjer Tebbens RJ. Lessons from the polio endgame: Overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. *Journal of Infectious Diseases* 2017; 216(S1):176-182.
141. Duintjer Tebbens RJ, Zimmermann MR, Pallansch MA, **Thompson KM**. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. *Food and Environmental Virology* 2017; 9(4):361-382, doi:10.1007/s12560-017-9314-4.
142. **Thompson KM**. Modeling and managing the risks of measles and rubella: A global perspective, Part II. *Risk Analysis* 2017; 37(6):1041-1051.
143. **Thompson KM**, Badizadegan ND. Modeling the transmission of measles and rubella to support global management policy analyses. *Risk Analysis* 2017; 37(6):1109-1131 (online 2017; May 31. doi:10.1111/risa.12831).
144. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt D, Farag N, Hadler S, Hampton LM, Martinez M, Wassilak SGF, **Thompson KM**. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in under-vaccinated subpopulations. *Risk Analysis* 2018; 38(8):1707-1717; (online January 3, doi:10.1111/risa.12962).
145. **Thompson KM**, Gellin BG, Hinman AR, Orenstein WA. The National Vaccine Advisory Committee at 30: Impact and opportunity. *Vaccine* 2018; 38(11):1330-1344.
146. Beigi R, Omer S, **Thompson KM**. Key steps forward for maternal immunization: Policy making in action. *Vaccine* 2018; 38(12):1521-1523.
147. Duintjer Tebbens RJ, Hampton LM, **Thompson KM**. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. *BMC Infectious Diseases* 2018; 8(1):165. doi:10.1186/s12879-018-3074-0.
148. Ozawa S, Yemeke T, **Thompson KM**. Systematic review of the costs of increasing immunization coverage. *Vaccine* 2018; 36(25):3641 (online May 10, doi.org/10.1016/j.vaccine.2018.05.030).
149. Kalkowska DA, Duintjer Tebbens RJ, **Thompson KM**. Another look at silent circulation of poliovirus in small populations. *Infectious Disease Modeling* 2018; 3:107-117.
150. Duintjer Tebbens RJ, **Thompson KM**. Using integrated modeling to support the global eradication of vaccine-preventable diseases. *System Dynamics Review* 2018; 34(1-2):78-120, doi:10.1002/sdr.1589.
151. Duintjer Tebbens RJ, Kalkowska DA, **Thompson KM**. Poliovirus containment risks and their management. *Future Virology* 2018; 13(9):617-628, doi:10.2217/fvl-2018-0079.
152. Duintjer Tebbens RJ, **Thompson KM**. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. *Expert Review of Vaccines* 2018; 17(8):739-751, doi:10.1080/14760584.2018.1506333.

153. Duintjer Tebbens RJ, **Thompson KM**. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. *Risk Analysis* 2019; 39(2):389-401 (online September 21, 2018, doi:10.1111/risa.13194).
154. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, **Thompson KM**. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Analysis* 2019; 39(2):402-413 (online October 8, 2018, doi:10.1111/risa.13214).
155. Kalkowska DA, Duintjer Tebbens RJ, **Thompson KM**. Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation in Pakistan and Afghanistan. *Risk Analysis* 2019;39(2):414-425 (online September 21, 2018, doi:10.1111/risa.13193).
156. Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, **Thompson KM**. Characterizing the costs of the Global Polio Laboratory Network: A survey-based analysis. *BMJ Open* 2019;9(1):e023290, doi:10.1136/bmjopen-2018-023290.
157. Duintjer Tebbens RJ, Kalkowska DA, **Thompson KM**. Global certification of wild poliovirus eradication: Insights from modeling hard-to-reach subpopulations and confidence about the absence of transmission. *BMJ Open* 2019;9(1):e023938, doi:10.1136/bmjopen-2018-023938.
158. **Thompson KM**, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). *Expert Review of Vaccines* 2019;18(7):725-736, doi:10.1080/14760584.2019.1635463.
159. Kalkowska DA, Pallansch MA, **Thompson KM**. Updated modeling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excretors. *Epidemiology & Infection* 2019;147:e295 (online October 24, 2019, doi:10.1017/S095026881900181X).
160. Vanlandingham DM, Hampton W, **Thompson KM**, Badizadegan K. Predictive modeling of anatomic pathology workload and complexity. *Risk Analysis* 2020;40(2):421-434 (online September 2, 2019, doi:10.1111/risa.13393).
161. **Thompson KM**., Orenstein WA, Hinman A. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019. *Vaccine* 2020;38(9):2136-2143 (online January 22, 2020, doi.org/10.1016/j.vaccine.2020.01.042).
162. Badizadegan K, Goodson JL, Rota PA, **Thompson KM**. The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization. *Expert Review of Vaccines* 2020;19(2):175-194, doi:10.1080/14760584.2020.1732215.
163. **Thompson KM**, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. *Expert Review of Vaccines* 2020;19(7):661-686, doi:10.1080/14760584.2020.1791093.
164. **Thompson KM**., Orenstein WA, Hinman A. An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery technologies and existing vaccines. *Vaccine* 2020;38(25):4060-4065 (online April 21, 2020, doi:10.1016/j.vaccine.2020.04.044).
165. Ochalek J, Claxton K, Lomas J, **Thompson KM**. Valuing health outcomes: Developing better defaults based on health opportunity costs. *Expert Review of Pharmacoeconomics & Outcomes Research* 2021;21(4):729-736 (online September 20, 2020 doi:10.1080/14737167.2020.1812387).
166. Vanlandingham DM, Hampton W, **Thompson KM**, Badizadegan K. Value of biopsy in a cohort of children with high-titer celiac serologies: Observation of dynamic policy

- differences between Europe and North America. *BMC Health Services Research* 2020;20:962, doi:10.1186/s12913-020-05815-0.
167. **Thompson KM**. Modeling poliovirus risks: We are where we are... *Risk Analysis* 2021;41(2):223-228, doi:10.1111/risa.13668.
  168. **Thompson KM**, Kalkowska DA. Reflections on modeling the poliovirus transmission and the polio eradication endgame. *Risk Analysis* 2021;41(2):229-247 (online April 27, 2020, doi:10.1111/risa.13484).
  169. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, **Thompson KM**. Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame. *Risk Analysis* 2021;41(2):248-265 (online January 21, 2020, doi:10.1111/risa.13447).
  170. Kalkowska DA, **Thompson KM**. Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan. *Risk Analysis* 2021;41(2):266-272 (online March 6, 2020, doi:10.1111/risa.13471).
  171. Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, **Thompson KM**. Modeling poliovirus transmission in Borno and Yobe, northeast Nigeria. *Risk Analysis* 2021;41(2):289-302 (online April 29, 2020, doi:10.1111/risa.13485).
  172. Kalkowska DA, **Thompson KM**. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in Northeast Nigeria. *Risk Analysis* 2021;41(2):303-311 (online April 29, 2020, doi:10.1111/risa.13486).
  173. Kalkowska DA, **Thompson KM**. Expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. *Risk Analysis* 2021;41(2):312-319 (online September 16, 2020, doi:10.1111/risa.13590).
  174. Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, **Thompson KM**. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. *Risk Analysis* 2021;41(2):320-328 (online July 6, 2020, doi:10.1111/risa.13555).
  175. Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay A, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, **Thompson KM**. Updated characterization of outbreak response strategies for 2019-2029: Impacts of using a novel type 2 oral poliovirus vaccine strain. *Risk Analysis* 2021;41(2):329-348 (online November 10, 2020, doi:10.1111/risa.13622).
  176. **Thompson KM**, Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. *Risk Analysis* 2021;41(2):349-363 (online July 9, 2020, doi:10.1111/risa.13557).
  177. Kalkowska DA, **Thompson KM**. Health and economic outcomes associated with polio vaccine policy options: 2019-2029. *Risk Analysis* 2021;41(2):364-375, doi:10.1111/risa.13664.
  178. **Thompson KM**, Kalkowska DA, Badizadegan K. A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States. *Risk Analysis* 2021;41(2):376-386 (online October 20, 2020, doi:10.1111/risa.13614), Letter: 2021;41(2):389-392, doi:10.1111/risa.13671.
  179. **Thompson KM**, Kalkowska DA. An updated economic analysis of the Global Polio Eradication Initiative. *Risk Analysis* 2021;41(2):393-406, doi:10.1111/risa.13665.
  180. **Thompson KM**, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. *Expert Review of Vaccines* 2021;20(4):465-481, doi:10.1080/14760584.2021.1891888.

181. **Thompson KM**, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication. *Expert Review of Vaccines* 2021;(4):449-460, doi:10.1080/14760584.2021.1891889.
182. Kalkowska DA, Pallansch MA, Cochi SL, **Thompson KM**. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options. *Journal of Infectious Diseases* 2021;224(9):1529-1538, doi:10.1093/infdis/jiab160.
183. Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, **Thompson KM**. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. *Vaccine* 2023;41(S1):A12-A18 (online April 27, 2021, doi:10.1016/j.vaccine.2021.04.026).
184. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, **Thompson KM**. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. *Vaccine* 2023;41(S1):A136-A141 (online May 13, 2021, doi:10.1016/j.vaccine.2021.04.061).
185. Kalkowska DA, Pallansch MA, Cochi SL, **Thompson KM**. Modeling of poliovirus surveillance and monitoring costs for Pakistan and Afghanistan for 2019-2023. *Open Forum Infectious Diseases* 2021;8(7):ofab264, doi:10.1093/ofid/ofab264.
186. **Thompson KM**, Badizadegan K. Health economic analyses of secondary vaccine effects - A systematic review and policy insights. *Expert Review of Vaccines* 2022;21(3):297-312 (online December 20, 2021, doi:10.1080/14760584.2022.2017287).
187. **Thompson KM**, Kalkowska DA, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. *Gates Open Research* 2022; 6:5, doi:10.12688/gatesopenres.13524.1.
188. Badizadegan K, Kalkowska DA, **Thompson KM**. Polio by the numbers – A global perspective. *Journal of Infectious Diseases* 2022;226(8):1309-1318, doi:10.1093/infdis/jiac130.
189. Kalkowska DA, Badizadegan K, **Thompson KM**. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. *Risk Analysis* 2023;43(4):660-676 (online June 23, 2022, doi:10.1111/risa.13983).
190. Kalkowska DA, Badizadegan K, **Thompson KM**. Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Analysis* 2023; ;43(4):677-685 (online June 23, 2022, doi:10.1111/risa.13982).
191. **Thompson KM**, Kalkowska DA, Badizadegan K. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. *Expert Review of Vaccines* 2022;(11):1667-1674, doi:10.1080/14760584.2022.2128108.
192. Kalkowska DA, Wassilak SGW, Pallansch MA, Burns CC, Wiesen E, Durry E, Badizadegan K, **Thompson KM**. Outbreak response strategies with type 2-containing oral poliovirus vaccines. *Vaccine* 2023;41(S1):A142-A152 (online November 16, 2022, doi:10.1016/j.vaccine.2022.10.060).
193. **Thompson KM**, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. *Frontiers in Public Health* 2023;11:1098419, doi:10.3389/fpubh.2023.1098419.
194. Kalkowska DA, Wassilak SGF, Wiesen W, Estivariz CF, Burns CC, Badizadegan K, **Thompson KM**. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. *Gates Open Research* 2023;7-55 (online April 17, 2023 gatesopenresearch.org/articles/7-55/v1).

195. Kalkowska DA, Badizadegan K, **Thompson KM**. Outbreak management strategies for cocirculation of multiple poliovirus types. *Vaccine* 2023; 41(25):3718-3727, doi:10.1016/j.vaccine.2023.04.037.
196. Kalkowska DA, Wassilak SGW, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, **Thompson KM**. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. *Risk Analysis* 2024;44(2):366-378 (online 21 June 2023, doi:10.1111/risa.14158).
197. Kalkowska DA, Wiesen E, Wassilak SGW, Burns CC, Pallansch MA, Badizadegan K, **Thompson KM**. Worst-case scenarios: Modeling uncontrolled type 2 poliovirus transmission. *Risk Analysis* 2024;44(2):379-389 (online 21 June 2023, doi:10.1111/risa.14159).
198. Badizadegan K, Kalkowska DA, **Thompson KM**. Health economic analysis of antiviral drugs in the global polio eradication endgame. *Medical Decision Making* 2023;43(7-8):850-862 (online 14 August 2023, doi:10.1177/0272989x231191127).
199. **Thompson KM**, Kalkowska DA, Routh JA, Brenner IR, Rosenberg ES, Zucker JR, Langdon-Embry M, Sugerman DE, Burns CC, Badizadegan K. Modeling poliovirus transmission and responses in New York State. *Journal of Infectious Diseases* 2024;229:1097-1106, (online 19 August 2023, doi:10.1093/infdis/jiad355).
200. **Thompson KM**, Kalkowska DA, Badizadegan K. Oral polio vaccine stockpile modeling: Insights from recent experience. *Expert Review of Vaccines* 2023;22(1):815-823 (online 29 September 2023, doi:10.1080/14760584.2023.2263096).
201. Kalkowska DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, Zucker JR, Langdon-Embry M, **Thompson KM**. Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. *Expert Review of Vaccines* 2024; 23(1):186-195 (online 4 January 2024, doi:10.1080/14760584.2023.2299401).
202. **Thompson KM**, Kalkowska DA, Kidd SE, Burns CC, Badizadegan K. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. *Vaccine* 2024;42(4):816-827 (online 3 January 2024, doi:10.1016/j.vaccine.2023.12.081).
203. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, **Thompson KM**, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter C, Lindstrand A, O'Brien KL, Bar-Zeev N. Contribution of vaccination to improved child survival: Modelling 50 years of the Expanded Programme on Immunization. *The Lancet* 2024; (online 2 May 2024, doi:10.1016/S0140-6736(24)00850-X).
204. **Thompson KM**, Badizadegan K. Review of poliovirus transmission and economic modeling to support global polio eradication: 2020-2024. *Pathogens* 2024;13(6):435, doi:10.3390/pathogens13060435.
205. **Thompson KM**, Badizadegan K. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs). *Expert Review of Vaccines* 2024;23(1):619-635 (online 1 June 2024, doi:0.1080/14760584.2024.2361060).
206. Badizadegan ND, Wassilak SGW, Estivariz C, Wiesen E, Burns CC, Bolu O, **Thompson KM**. Intensification of population immunity prior to globally-coordinated cessation of bivalent oral poliovirus vaccine (bOPV). *Pathogens* 2024;13(9):804, doi:10.3390/pathogens13090804.

## ***Committee Reports***

1. National Vaccine Advisory Committee (Orenstein WA, Gellin, BG, Beigi RH, Despres S, Lynfield R, Maldonado Y, Mouton C, Rawlins W, Rothholz MC, Smith N, **Thompson KM**, Torres C, Viswanath K, Hosbach P). Assessing the state of vaccine confidence in the United States: Recommendations from the National Vaccine Advisory Committee. *Public Health Reports* 2015; 130(6):573-95.
2. National Vaccine Advisory Committee (Orenstein WA, Gellin, BG, Beigi RH, Despres S, Lynfield R, Maldonado Y, Mouton C, Rawlins W, Rothholz MC, Smith N, **Thompson KM**, Torres C, Viswanath K, Hosbach P). Overcoming barriers to low HPV vaccine uptake in the United States: Recommendations from the National Vaccine Advisory Committee. *Public Health Reports* 2016; 131(1):17-25.
3. National Vaccine Advisory Committee (Orenstein WA, Gellin, BG, Beigi RH, Despres S, Lynfield R, Maldonado Y, Mouton C, Rawlins W, Rothholz MC, Smith N, **Thompson KM**, Torres C, Viswanath K, Hosbach P). A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: Recommendations from the National Vaccine Advisory Committee. *Public Health Reports* 2016; 131(1):1-16.
4. National Vaccine Advisory Committee (Orenstein WA, **Thompson KM**, Gellin, BG, Beigi RH, Despres S, Fleming D, Ginsberg A, Lynfield R, Maldonado Y, Omer S, Rawlins W, Rothholz MC, Smith N, Cooke T, Hosbach P). Overcoming barriers and identifying opportunities for developing maternal immunizations: Recommendations from the National Vaccine Advisory Committee. *Public Health Reports* 2017; 132(1):1-14.
5. National Vaccine Advisory Committee (**Thompson KM**, Gellin, BG, Black R, Butler JC, Butler MA, Despres S, Fleming D, Ginsberg A, Hopkins RH, Lynfield R, Maldonado Y, Omer S, Rawlins W, Rothholz MC, Smith N, Hosbach P, Cooke T). Evaluation of the 2010 National Vaccine Plan mid-course review: Recommendations from the National Vaccine Advisory Committee. *Public Health Reports* 2017; 132(4):1-20.
6. National Vaccine Advisory Committee (**Thompson KM**, Shen AK, Black S, Butler JC, Butler MA, Dunn J, Fleming D, Ginsberg A, Hopkins RH, Jackson MA, Martinez M, Meissner HC, Omer S, Pickering L, Smith N, Swamy G, Cooke T, Friedland). Strengthening the effectiveness of national, state, and local efforts to improve HPV vaccination coverage in the United States: Recommendations of the National Vaccine Advisory Committee. *Public Health Reports* 2018; online August 9, doi:10.1177/0033354918793629.
7. Joffe AM, Park E-C, Augustine A, Jiang C, PrabhuDas M, Vazquez-Maldonado N, Aaby P, Alter G, Divangahi M, Hotez P, Khader S, Netea, MG, Petri WA, Plotkin S, **Thompson KM**, SVE Workshop Committee. NIAID workshop on secondary vaccine effects. *Nature Immunology* 2021; doi:10.1038/s41590-021-01054-5.

## ***Selected Editorials and Perspectives***

1. Burmaster DE, **Thompson KM**. The draft Exposure Factors Handbook: EPA can probably fix it. A commentary. *Risk Policy Report* 1997; 3(1):35-38.
2. **Thompson KM**, Graham JD. Reducing risk by conserving fuel and recovering wasted heat. *Risk in Perspective* 1997; 5(9):September. Boston, MA: Harvard Center for Risk Analysis.
3. **Thompson KM**. Integrated policy analysis: The best of all worlds, but can we get there from here? *Risk Policy Report* 1999; 6(6):41-43. Reprinted in *Risk Management Reports*, 1999; 26:9, September.



4. **Thompson KM.** Health insight: A consumer's guide to taking charge of health information. *Risk in Perspective* 1999; 7(7) October. Boston, MA: Harvard Center for Risk Analysis (see web sites). Reprinted in *Consumers' Research* as "Ten initial questions about health information," 2000; February 27-29 and in *Electric Perspectives* as "It ain't necessarily so: Ten simple questions can help consumers evaluate health risks," 2000; March/April:22-26.
5. **Thompson KM.** Kids at Risk. *Risk in Perspective* 2000; 8(4) April. Boston, MA: Harvard Center for Risk Analysis (see web sites). Edited and reprinted as Chapter 8 in *Are Children More Vulnerable to Environmental Chemicals? Scientific and Regulatory Issues in Perspective*, Juberg, DR (ed). New York, NY: American Council on Science and Health, 2002.
6. **Thompson KM.** Even in America, children are at risk. *Newsday*; Long Island, NY; May 5, 2002.
7. **Thompson KM.** Editorial. Communication in the age of risk management. *Human and Ecological Risk Assessment* 2003; 9(1):1-3.
8. **Thompson KM.** Children are our present. *The New York Times*; New York, NY; December 26, 2003.
9. **Thompson KM.** Film, game ratings often mislead. *Orlando Sentinel*; Orlando, FL; August 1, 2004.
10. **Thompson KM.** Kids and media: Learning happens. *Medscape General Medicine* 2005 (June 10); 7(2) (available at: <http://www.medscape.com/viewarticle/505766>).
11. **Thompson KM.** Not zero risk – But lifesaving. *Orlando Sentinel*; Orlando, FL; October 23, 2005.
12. **Thompson KM.** Guest editorial: By the numbers. *Police Magazine*; January 2006, p. 9.
13. **Thompson KM.** KidsRisk Guide on Media and Kids. Harvard School of Public Health, April 2006 (available at <https://kidsrisk.org/mediaguide.html>).
14. **Thompson KM.** Eradicating polio: The dollars and sense. *Medscape General Medicine* 2007 (October 15); 9(4) (available at: <http://www.medscape.com/viewarticle/563895>).
15. **Thompson KM.** Reforms for rating media: Disclosure, not censorship. *Medscape General Medicine* 2007 (November 5); 9(4) (available at: <http://www.medscape.com/viewarticle/564596>).
16. **Thompson KM.** Food insight: Managing the risks of eating. 2007 (available at: [www.voila.harvard.edu](http://www.voila.harvard.edu) and [www.food-insight.org](http://www.food-insight.org)).
17. **Thompson KM.** Discussion on Welton et al. "Research prioritization based on expected value of partial perfect information: A case study on interventions to increase uptake of breast cancer screening." *Journal of the Royal Statistical Society: Series A* 2008;(171, Part 4): 838-839.
18. **Thompson KM.** The role of risk analysis in polio eradication: Modeling possibilities, probabilities, and outcomes to inform choices. *Expert Review of Vaccines* 2012; 11(1):5-7.
19. **Thompson KM.** Polio endgame management: Focusing on performance with or without inactivated poliovirus vaccine. *The Lancet* 2014; 384(9953):1480-2 (online July 11, doi:10.1016/S0140-6736(14)60983-1).
20. **Thompson KM.** Good news for billions of children who will receive IPV. *The Lancet Infectious Diseases* 2015; 15(10):1120-22. (online August 16, doi:10.1016/S1473-3099(15)00099-7), Letter 2016; 16(4):410.
21. **Thompson KM, Duintjer Tebbens RJ.** How should we prepare for an outbreak of reintroduced live polioviruses? *Future Virology* 2017; 12(2):41-44, doi:10.2217/fvl-2016-0131.

22. **Thompson KM.** What will it take to end human suffering from measles? *The Lancet Infectious Diseases* 2017; 17(10):1013-1014 (online Aug 11, doi:10.1016/S1473-3099(17)30451-6).
23. **Thompson KM.** What will it take to end fatalities from measles? *The Lancet Global Health* 2019; 7(4): e394-5 (online Feb 20, doi:10.1016/S2214-109X(19)30050-6).
24. **Thompson KM.** Polio endgame options: Will we have the vaccines needed? *The Lancet* 2019; 394(10193):99-100 (online June 4, doi:10.1016/S0140-6736(19)31294-2).
25. **Thompson KM.** Poliovirus vaccine options: Another step forward. *The Lancet* 2020; 397(10268):2-3 (online Dec 9, doi:10.1016/S0140-6736(20)32629-5).
26. **Thompson KM.** Polio eradication: What kind of world do we want? *The Lancet Infectious Diseases* 2022; 22(2):161-163 (online Oct 11, 2021, doi:S1473-3099(21)00458-8).
27. **Thompson KM, Badizadegan KM.** Global implications of polio in the United States in 2022. *Infectious Diseases Society of America Science Speaks Blog* 2022; <https://www.idsociety.org/science-speaks-blog/2022/global-implications-of-polio-in-the-united-states-in-2022/> (online Sep 13).
28. **Thompson KM.** Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. *The Lancet Global Health* 2022; 10(12):e1697-1698 (online Dec 21, 2022, doi:10.1016/S2214-109X(22)00452-1).
29. **Thompson KM, Lauring AS, Pollard AJ, Andino R, Bandyopadhyay AS, Berkley S, Bhutta ZA, Routh J, Benn CS.** Polio eradication: Addressing the hurdles on the last mile. *Cell* 2023;186(1):1-4. doi:10.1016/j.cell.2022.12.021.
30. **Thompson KM.** Complexity in the polio end game: Updating expectations for nOPV2. *The Lancet Infectious Diseases* 2023; 23(9):992-994 (online May 10, 2023, doi:10.1016/S1473-3099(23)00133-0).
31. **Thompson KM.** Excess vaccine-preventable disease mortality due to COVID-19. *The Lancet Global Health* 2024; 12(4):e531-e532. doi:10.1016/S2214-109X(24)00046-9.

***Selected Articles in Conference Proceedings (Not otherwise published)***

1. **Thompson KM, Koutrakis P, Brauer M, Spengler JD, Wilson WE, Burton RM.** Measurements of aerosol acidity: Sampling frequency, seasonal variability, and spatial variation, Paper number 91-89.5, Proceedings of the 84th Annual AWMA Conference, Vancouver, BC, Canada, June 1991.
2. **Thompson KM, Segui-Gomez M, Graham JD.** Learning from the past: Revisiting expert judgments related to the lifesaving potential of air bags. Probabilistic Safety Assessment and Management, Mosleh, A. and R.A. Bari (eds), New York, NY: Springer, 1998; Volume 3:2107-2112.
3. **Thompson KM.** Insights for Y2K risk reporting. Proceedings of the National Y2K Summit on Public Preparedness versus Public Panic held on September 17, 1999 at the Freedom Forum World Center in Arlington, Virginia. Pasadena, CA: Foundation for American Communications.
4. **Thompson KM.** Making sense of risk: Development of a guide to help people take charge of health information. Proceedings of the American Statistical Association, Joint Government and Social Statistics Sections, Alexandria, VA: American Statistical Association 2000;67-73.
5. **Thompson KM, Graham JD, Zellner JW.** Risk-benefit analysis methods for vehicle safety devices. Proceedings of the 17<sup>th</sup> International Technical Conference of the Enhanced Safety of Vehicles, Amsterdam, Paper Number 01-S4-O-340, 2001.

6. **Thompson KM.** Navigating the maze: Federal activities to address children's environmental health risks. In *Children's Environmental Health: What Role for the Federal Government?* Printed for the Senate Committee on Environment and Public Works, 107<sup>th</sup> Congress, 2<sup>nd</sup> Session, Senate Report 107-62, Washington, DC: U.S. Government Printing Office 2001; 151-169.
7. **Thompson KM,** Duintjer Tebbens RJ. Modeling global policy for managing polioviruses: An analytical journey. Presented at System Dynamics Society 2005 Annual Meeting, Boston, MA. <http://www.systemdynamics.org/conferences/2005/proceed/papers/THOMP452.pdf>.
8. Duintjer Tebbens RJ, **Thompson KM.** On the characterization of censored survival curves in system dynamic models. Presented at System Dynamics Society 2015 Annual Meeting, Boston, MA. Available at: <http://www.systemdynamics.org/web.portal?A1359+0>.
9. **Thompson KM.** Wiping out polio: Reflections on winning the 2014 Franz Edelman Award. INFORMS Edelman Gala Book, Huntington Beach, CA: April 13, 2015; 11-13.
10. **Thompson KM,** Kisjes KH, Duintjer Tebbens RJ. Characterization of the impacts of heterogeneity in high-risk populations for infectious disease transmission: Modeling polio and measles in the North American Amish. Presented at System Dynamics Society 2015 Annual Meeting, Boston, MA. <http://www.systemdynamics.org/web.portal?A1355+0>.

## **Books**

### Popular books

1. **Thompson KM** with D.F. Bruce. Overkill: How our nation's abuse of antibiotics and other germ killers is hurting your health and what you can do about it. Emmaus, PA: Rodale 2002. (Translated into Arabic.)
2. **Thompson KM.** Risk in perspective: Insight and humor in the age of risk management. Newton, MA: AORM 2004.

### Book chapters

1. Hammitt JK, **Thompson KM.** Protecting the ozone layer. Chapter 3 in The Greening of Industry: A Risk Management Approach, Graham JD and J.K. Hartwell (eds). Cambridge, MA: Harvard University Press, 1997; 43-92.
2. **Thompson KM.** Cleaning up dry cleaners. Chapter 4 in The Greening of Industry: A Risk Management Approach, Graham JD and J.K. Hartwell (eds). Cambridge, MA: Harvard University Press, 1997; 93-135.
3. **Thompson KM,** Graham JD. Producing paper without dioxin pollution. Chapter 7 in The Greening of Industry: A Risk Management Approach, Graham JD and J.K. Hartwell (eds). Cambridge, MA: Harvard University Press, 1997; 203-268.
4. Carrothers TJ, **Thompson KM,** Burmaster DE. Risk Assessment, Probabilistic. In Encyclopedia of Environmetrics, Abdel El-Shaarawi and Walter Piegorsch (eds.), 2002; Volume 3, pp. 1833-1837.
5. **Thompson KM.** Kids at Risk. Edited and reprinted as Chapter 8 in Are Children More Vulnerable to Environmental Chemicals? Scientific and Regulatory Issues in Perspective, Juberg, DR (ed). New York, NY: American Council on Science and Health, 2002.
6. **Thompson KM.** Foreword. In Bringing up geeks: How to protect your kid's childhood in a grow-up-too-fast world, Hicks, M. New York, NY: Berkley Books 2008.

7. **Thompson KM**, Duintjer Tebbens RJ. Challenges related to the economic evaluation of the direct and indirect benefits and the costs of disease elimination and eradication efforts. Chapter 9 in Disease Eradication in the 21st Century: Implications for Global Health, Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press, 2011; 115-130.
8. **Thompson KM**, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker DG. Developing an Eradication Investment Case. Chapter 10 in Disease Eradication in the 21st Century: Implications for Global Health, Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press, 2011; 133-148.
9. **Thompson KM**. Risk Assessment, Probabilistic. In Encyclopedia of Environmetrics, 2<sup>nd</sup> Edition, Abdel El-Shaarawi and Walter Piegorsch (eds.), 2012.
10. **Thompson KM**. Making a difference. Chapter 10 in Governance in the Information Era: Theory and Practice of Policy Informatics, Johnston EW (ed). Oxford, UK: Routledge Press, 2015; 174-186.
11. Medeiros CB, Kum H-C, Sandin S, Schmit CD, **Thompson KM**, Tiemeier H, Kaski K. Integrating knowledge from individual data to population-level data. Chapter 5 in Digital Ethology: Human Behavior in Geospatial Context, Paus T and Kum H-C (eds). Cambridge, MA: MIT Press, 2024; 79-104.

#### Book and software reviews

1. **Thompson KM**. Software review of Risk\*Assistant (Version 1.1) and RiskEZ (Version 1), both for windows. *Human and Ecological Risk Assessment* 1998; 4(3):647-652.
2. **Thompson KM**. Software review of @RISK BestFit and Crystal Ball distribution fitting programs. *Human and Ecological Risk Assessment* 1999; 5(3):501-508.
3. **Thompson KM**. Book review: Should we risk It? Exploring environmental, health, and technological problem solving by Daniel M. Kammen and David M. Hazzenzahl. *Journal of Policy Analysis and Management* 2000; 19(4):669-671.

#### Selected Other Reports (Not otherwise published)

1. **Thompson KM**. Risk Analysis in a Complicated World. In Executive Research Group, Managing the Environment: A Report of Best Practices, Volume II, Chapter 10, published by the Government of Ontario, Ministry of the Environment, 2001 (available at: [http://www.ene.gov.on.ca/envision/ergreport/downloads/report\\_paper10.pdf](http://www.ene.gov.on.ca/envision/ergreport/downloads/report_paper10.pdf)).
2. **Thompson KM**. How much do kids count in corporate board rooms? Results from the first survey of Fortune 1000 companies. Newton, MA: AORM 2004. (Full report that corresponds to peer-reviewed paper number 36 that includes statements and quotes from companies and their leaders).
3. **Thompson KM**, Armstrong AE, Thompson DF. Wither Bioterrorism: Bayes, bugs, and bioterrorists: Lessons learned from the anthrax attacks. Washington, DC: National Defense University, Center for Technology and National Security Policy 2005.

#### Non-print materials

Web sites created and maintained:

[www.kidrisk.org](http://www.kidrisk.org) (2009-present)

[www.voila.harvard.edu](http://www.voila.harvard.edu) (2007-2010) now at: [www.food-insight.org](http://www.food-insight.org)

[www.aorm.com](http://www.aorm.com) (2002-present)

www.kidsrisk.harvard.edu (2000-2010) now at: www.kidsrisk.org  
www.pracourse.harvard.edu (2000-2010)  
www.health-insight.harvard.edu (1999-2010) now at: www.health-insight-harvard.org

## MEETINGS ORGANIZED

### Harvard

- Co-organized and co-hosted (with Dr. Michael Rich) a one-day symposium called “Media and Child Health: Peril and Promise” held October 2001 that included 2 presentations and moderating.
- Organized and hosted a two-day symposium called “Managing Children’s Risks: It Takes a Commitment” held March 26-27, 2003 at Harvard University that included 3 presentations and moderating.
- Organized and hosted a one-day symposium called “Managing Children’s Risks: Putting All Children Ahead” at the Harvard School of Public Health held July 30, 2008 that included presenting and moderating.

### Society for Risk Analysis

- Responsible for organizing the 2006 Annual Meeting “Risk Analysis in a Dynamic World: Making a Difference” (Chair of the SRA Annual Meeting Committee).

## TEACHING EXPERIENCE

University of Central Florida, College of Medicine. Authored teaching case on Middle East Respiratory Syndrome (MERS-CoV), co-authored teaching case on polio, and ran “Friday Night at the ER” management simulation for 4<sup>th</sup> year M.D. students (2013).

Harvard University, School of Public Health. Taught Environmental Health Risk: Concepts and Cases (ID285, Winter 2003, 2004, 2005, 2008, and HPE285d, Spring 2001, 2002), developed and taught Analytical Methods for Risk Analysis and Decision Science (HPE301a, Fall 2000 and HPE299d, Spring 2000 and HPE301d, Spring 1998), taught Seminar in Risk Analysis, Management, and Communication (HPE285d, Spring 2000), co-taught Seminar in Risk Analysis, Management, and Communication (HPE285d, Spring 1998 and Spring 1999) with Professor John Graham, co-taught Seminar in Risk Analysis (HPE285b, Fall 1996) with Professor John Graham, developed and directed Continuing Education Course on Probabilistic Risk Analysis: Assessment, Management, and Communication (2000, 2001, 2002, 2003, 2004) also offered at Health Canada in March 2002, lectured in Continuing Education courses for Analyzing Risk: Science, Assessment, and Management (Principles of Exposure Assessment) (1997 to 2000), Benefit-Cost Analysis for Environmental, Health, and Safety Regulation (Air Toxics, Uncertainty, and the Value of Information) (1997 to 1999), and The Risk Communication Challenge (Comparing Risks) (1999 to 2000).

Harvard University, University-wide Health Policy Program, Lectured on Environmental Health in the Doctoral Health Policy Core Seminar (Fall 1997, 1998, 1999).

Massachusetts Institute of Technology. Taught System Dynamics (15.871/15.874/15.962, Spring 2006, 2007). Also taught Risk Analysis in the MIT-BP Projects Academy (Spring and Summer 2006). Lectured in the Medical Evidence Boot Camp, Knight Science Journalism Fellowship Program (2005, 2006, 2007). Member of the MIT Biomedical Enterprise Program

Faculty Steering Committee (2006-2008). Guest lecturer in Engineering Risk-Benefit Analysis (Spring 2004, 2007). Lecturer in Supply Chains Driving Strategic Advantage: Managing Dynamics and Innovating the Future, professional education course (2007, 2008).

Co-directed a 1-day course on Probabilistic Risk Assessment at the Society for Risk Analysis Annual Meeting (with Dr. David Burmaster) (1998).

## **RESEARCH SUPERVISION**

### Doctoral Theses, Research Supervisor

- Fumie Yokota, “Improving Value of Information Analysis in Health Risk Management,” June 2003.
- Radboud J. Duintjer Tebbens, “Quantitative Analysis of Trade-Offs and Model Input Sensitivities in Public Health,” TU Delft, The Netherlands, October 2005.

### Doctoral Theses, Committee Member

- Pamela D. Williams, “A Comparison of Food Safety Risks: Science, Perceptions and Values,” Harvard University, Environmental Science and Risk Management, June 1999.
- Gwangpyo Ko, “Reduction in Tuberculosis Transmission by Ultraviolet Germicidal Irradiation and Related Microbial Risk Assessment,” Harvard University, Environmental Health, June 2000.
- Christopher Long, “An Investigation of the Impacts of Indoor and Outdoor Particle Sources in Indoor Residential Environments,” Harvard University, Environmental Health, November 2000.
- Knashawn Hodge Morales, “Statistical Methods for Risk Assessment Based on Epidemiological Data,” Harvard University, Biostatistics, June 2001.
- Chen-Chang Yang, “Predictors of Drug Utilization and Certain Pharmacological Effects of Lipid-Lowering Drugs in the United Kingdom,” Harvard University, Epidemiology, May 2002.
- Amy Vinturella, “Partitioning of Bioavailability of Polycyclic Aromatic Hydrocarbons in Marine Sediments: Implications for Human and Ecological Health,” Harvard University, Environmental Health, June 2003.
- Anne M. Riederer, “Multimedia Human Exposures to Developmental Toxicants in the Philippines,” Harvard University, Environmental Health, June 2004.
- Katherine von Stackelberg, “Contingent valuation for ecological and noncancer risk reductions within an integrated human health and ecological risk framework” Harvard University, Environmental Science and Risk Management, November 2006.
- Janet Rosenbaum, “Reborn a virgin: The validity of adolescent self-report of risk behaviors and the efficacy of abstinence pledges as a marker of subsequent sexual activity,” Harvard University, Health Policy, November 2007.
- Eileen Sandberg, “The health-related quality of life of children ages 7-10 years with Attention Deficit Hyperactivity Disorder (ADHD) and the cost-effectiveness of treating ADHD in these children,” Harvard University, Health Policy, November 2008.
- David Opolon, “Improving Product Availability in Hospitals: The Role of Inventory Inaccuracies” MIT Engineering Systems Division, January 2010.
- Dominika A. Kalkowska, current, TU Delft, The Netherlands.

### Post-doctoral Fellow Supervisor

- Radboud J. Duintjer Tebbens, 2005-2008
- Jong-Hoon Kim, 2010-2011

### Medical Student Research Supervisor

- Emily Simons, Harvard Medical School, 2012-2013.
- Deeva Berera, University of Central Florida, College of Medicine, 2012-2014.
- Wendy Carcamo, University of Central Florida, College of Medicine, 2012-2013.
- Julia Heizmann, University of Central Florida, College of Medicine, 2012-2013.
- Jill Ireland, University of Central Florida, College of Medicine, 2013-2014.
- Nhuhang Ho, University of Central Florida, College of Medicine, 2012-2013.
- Grace Logan, University of Central Florida, College of Medicine, 2012-2014.
- Michael Lienhard, University of Central Florida, College of Medicine, 2012-2013.
- Michael Norred, University of Central Florida, College of Medicine, 2012-2014.
- Monika Walankiewicz, Research exchange, summer 2014.

### Master's Theses, Research Supervisor

- R. Frank Rabouw, “Living Near an Airport, Risky or Just Annoying?” TU Delft, The Netherlands, October 2000.
- Radboud J. Duintjer Tebbens, “Dynamics and Sensitivities in Cost-effectiveness Analyses for Vaccine Interventions,” TU Delft, The Netherlands, March 2002.
- Amir Sundrani, “Understanding Social Amplification of Risk: Possible Impact of an Avian Flu Pandemic,” MIT LFM, June 2007 (served as MIT Sloan School supervisor, Charles L. Cooney served as School of Engineering Supervisor).
- Daniel Rippey, “Assessing Decision Inputs in Drug Development between Small, Early Stage Companies and Big Pharma: Is There a Difference?” MIT HST Biomedical Enterprise Program, August 2007 (served as co-advisor with Fiona Murray).
- Dominika A. Kalkowska, “Polio eradication: A stochastic approach to modeling hidden circulation of wild polioviruses” TU Delft, The Netherlands, September 2010 (served as co-advisor with Radboud Duintjer Tebbens).

### Bachelor's Theses, Research Supervisor

- M. Seamus Ryan, “Environmental Regulations vs. International Trade: A WTO Ruling on Venezuelan Gasoline Imports into the United States,” Harvard College, Environmental Science and Public Policy, June 2001 (Senior Thesis, won a Harvard University Thomas T. Hoopes Prize).
- Kasper Kisjes, “Individual-based modeling of potential poliovirus transmission in a religious community.” TU Delft, The Netherlands, August 2010.

## **WORK/CONSULTING EXPERIENCE**

Organization	Beginning	Ending
Procter & Gamble, Richardson Vicks (summer)	June 1988	August 1988
Alceon Corporation (full time)	September 1989	June 1990

Alceon Corporation (part time, small projects)	June 1990	September 1997
Abt Associates	August 1995	December 1995
Marasco-Netwon Group	October 1996	June 1997
U.S. Air Force	May 1997	September 1997
Battelle	August 1997	September 1997
ChemRisk Corporation	July 1997	December 1997
International Life Sciences Institute	February 1998	November 1998
American Council on Science and Health	February 1999	June 1999
Argonne National Laboratory	March 2000	May 2000
U.S. Environmental Protection Agency	June 2000	September 2000
Executive Research Group	October 2000	January 2001
U.S. Food and Drug Administration	December 2000	February 2001
Bayer	March 2001	March 2001
MIT Lincoln Laboratory	June 2001	April 2002
Flynn, Gaskins & Bennett	August 2001	February 2002
National Defense University	March 2003	October 2004
NIH, Center on Bioethics	May 2003	September 2003
American Chemistry Council	July 2003	August 2003
Mattel	January 2004	April 2004
Lincolnshire, LLC	February 2004	May 2005
U.S. Food and Drug Administration	July 2004	September 2004
The Scotts Company	December 2004	March 2005
Environ Corporation/DuPont	June 2005	September 2006
Procter & Gamble	June 2005	June 2015
Merck	October 2005	October 2006
MegaBloks	March 2006	August 2006
Dow Chemical Company	September 2006	September 2008
Genzyme	September 2006	September 2006
FoodMinds, LLC	June 2006	December 2007
Versar, Inc.	August 2008	September 2008
Kimberly Clark	August 2008	December 2008
Dynamic Research	November 2011	December 2011
Alliance of Blood Operators	April 2015	May 2015
Nationwide Children's Hospital	January 2018	June 2018
Merck	November 2018	November 2018
ModernaTX, Inc.	December 2020	December 2020
Novavax	February 2022	February 2022
Novavax	January 2023	January 2023

## POPULAR MEDIA COVERAGE OF RESEARCH

*Selected Television:* Interviewed on ABC World News Tonight, CBS Evening News, TODAY, CBS The Morning Show, CNBC, CNN, ESPN, C-SPAN2, MSNBC, Canada Today, The Australian Today Show, JAMA video news release, and all Boston local network news stations, and appeared in an episode of FETCH!

*Selected Radio:* NPR, BBC, Canadian Broadcasting Corporation, CBS, ABC, numerous local radio stations around the world



*Selected Print:* New York Times (including Science Times and source of the Quotation of the Day for July 14, 2004), Wall Street Journal, USA Today, LA Times, Chicago Times, Washington Post, Boston Globe (front page), Boston Herald (front page), Orlando Sentinel, Scotland on Sunday, hundreds of local papers that carried one of several Associated Press and Reuters pieces, US News & World Report, Newsweek, Time Magazine, Harper's Magazine, Better Homes and Gardens, Parents Magazine, Child Magazine, Reason Magazine, Business Week, Nature, Discover Magazine, Fitness Magazine, Realtor Magazine, American Way Magazine, Sports Illustrated, Parents' Paper, and Wired Magazine